Mary O’Brien

26.4k total citations · 4 hit papers
273 papers, 17.2k citations indexed

About

Mary O’Brien is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Mary O’Brien has authored 273 papers receiving a total of 17.2k indexed citations (citations by other indexed papers that have themselves been cited), including 175 papers in Pulmonary and Respiratory Medicine, 164 papers in Oncology and 36 papers in Epidemiology. Recurrent topics in Mary O’Brien's work include Lung Cancer Treatments and Mutations (123 papers), Lung Cancer Research Studies (68 papers) and Lung Cancer Diagnosis and Treatment (62 papers). Mary O’Brien is often cited by papers focused on Lung Cancer Treatments and Mutations (123 papers), Lung Cancer Research Studies (68 papers) and Lung Cancer Diagnosis and Treatment (62 papers). Mary O’Brien collaborates with scholars based in United Kingdom, United States and Germany. Mary O’Brien's co-authors include Julie R. Brahmer, Delvys Rodríguez‐Abreu, Martin Reck, Sinéad Cuffe, Ali Tafreshi, Rina Hui, Katsuyuki Hotta, Nir Peled, Suman Rao and Maya Gottfried and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Contemporary Sociology A Journal of Reviews.

In The Last Decade

Mary O’Brien

267 papers receiving 16.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

2016 7.1k citations Mary O’Brien et al. profile →
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1997 691 citations David Cunningham, Mary O’Brien et al. Journal of Clinical Oncology profile →
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

2021 616 citations Mary O’Brien et al. Journal of Clinical Oncology profile →
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

2017 354 citations Fabrice Barlési, Mary O’Brien et al. profile →

Peers

Countries citing papers authored by Mary O’Brien

Since Specialization

Citations

This map shows the geographic impact of Mary O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary O’Brien more than expected).

Fields of papers citing papers by Mary O’Brien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary O’Brien. The network helps show where Mary O’Brien may publish in the future.

Co-authorship network of co-authors of Mary O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Mary O’Brien. A scholar is included among the top collaborators of Mary O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary O’Brien. Mary O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Schild Analysis of the Interaction between Parthenolide and Cocaine Suggests an Allosteric Relationship for Their Effects on Planarian Motility 2024 ·Biomolecules ·(unknown), Mary O’Brien, Oné R. Pagán	1
2	81 Evaluation of neoadjuvant chemo-immunotherapy for operable non-small cell lung cancer: clinical outcomes and impact on service delivery 2024 ·Lung Cancer ·(unknown), (unknown), Faisal Rehman, (unknown), (unknown), (unknown), (unknown), Nadia Yousaf, (unknown), Carol Tan, Jeremy Smelt, Ian Hunt, Simon Jordan, Sofina Begum, Jaishree Bhosle, Anna Minchom, (unknown), Sanjay Popat, Mary O’Brien, Michael Davidson	0
3	Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes 2022 ·Molecular Cancer Therapeutics ·Elizabeth A. Coker, Adam Stewart, Buğra Özer, Anna Minchom, Lisa Pickard, Ruth Ruddle, Suzanne Carreira, Sanjay Popat, Mary O’Brien, Florence I. Raynaud, Johann S. de Bono, Bissan Al‐Lazikani, Udai Banerji	8
4	Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond 2021 ·Lung Cancer ·Kroopa Joshi, (unknown), (unknown), (unknown), Nadia Yousaf, Sanjay Popat, Michael Davidson, Jaishree Bhosle, Mary O’Brien, Anna Minchom	5
5	The use of telepsychiatry during COVID-19 and beyond 2020 ·Irish Journal of Psychological Medicine ·Mary O’Brien, Fiona McNicholas	96
6	1315P Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer) 2020 ·Annals of Oncology ·Enriqueta Felip, (unknown), Melissa L. Johnson, Mary O’Brien, Fabrice Barlési, Julien Mazières, Benjamin Solomon, Víctor Moreno, Valentina Boni, Aurélie Swalduz, Sarah B. Goldberg, Bhumsuk Keam, Steven G. Allen, (unknown), Colby S. Shemesh, (unknown), N. Al-Sakaff, (unknown), Pakeeza Sayyed, Byoung Chul Cho	6
7	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS -Mutant Cancers 2019 ·Molecular Cancer Therapeutics ·Adam Stewart, Elizabeth A. Coker, Sebastian Pölsterl, (unknown), Anna Minchom, Suzanne Carreira, David Cunningham, Mary O’Brien, Florence I. Raynaud, Johann S. de Bono, Bissan Al‐Lazikani, Udai Banerji	14
8	nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial 2018 ·Drug Design Development and Therapy ·Cesare Gridelli, Tianlei Chen, Amy Ko, Mary O’Brien, Teng Jin Ong, Mark A. Socinski, Pieter E. Postmus	7
9	Performance verification for robot missions in uncertain environments 2017 ·Robotics and Autonomous Systems ·Damian M. Lyons, Ronald C. Arkin, Shaohua Jiang, Mary O’Brien, (unknown), Peng Tang	10
10	A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma 2016 ·European Journal of Cancer ·Anna Minchom, (unknown), Jacqueline Filshie, Jaishree Bhosle, Kofi Nimako, (unknown), R. Gunapala, Sanjay Popat, Mary O’Brien	37
11	Heterogeneity of 18F-FDG PET uptake: Association with treatment response and prognosis in non-small cell lung cancer treated with erlotinib. 2015 ·Radiology ·Gary Cook, Mary O’Brien, (unknown), Sugama Chicklore, (unknown), Bhupinder Sharma, (unknown), Paul Bassett, Vicky Goh, Sue Chua	5
12	Modafinil for the Treatment of Fatigue in Lung Cancer: Results of a Placebo-Controlled, Double-Blind, Randomized Trial 2014 ·Journal of Clinical Oncology ·Anna Spathis, Kate Fife, Fiona Blackhall, Susan Dutton, (unknown), Rose Wharton, Mary O’Brien, Patrick Stone, T. Benepal, Nick Bates, Bee Wee	78
13	A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors 2014 ·Molecular Cancer Therapeutics ·Kari Kendra, Ruth Plummer, Ravi Salgia, Mary O’Brien, Elaine Paul, (unknown), Natalie Compton, Chun‐Fang Xu, Lone H. Ottesen, Miguel A. Villalona‐Calero	28
14	A phase II study of 18F-fluorodeoxyglucose PET–CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12weeks 2011 ·European Journal of Cancer ·Mary O’Brien, (unknown), Jermaine Coward, M. Puglisi, Leonardo Trani, Andrew Wotherspoon, Bhupinder Sharma, Gary Cook, S. Ashley, R. Gunapala, Sue Chua, Sanjay Popat	24
15	Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062 2011 ·European Journal of Cancer ·Mary O’Brien, (unknown), Paul Lorigan, Lionel Bosquée, Ernest Marshall, F. Bustin, (unknown), Christian Fink, Jos A. Stigt, Anne‐Marie C. Dingemans, Baktiar Hasan, Jan P. van Meerbeeck, Paul Baas	21
16	Clinical experience of IMGN901 (BB-10901) in patients with small cell lung carcinoma (SCLC) 2009 ·Journal of Thoracic Oncology ·Frank V. Fossella, Penella J. Woll, Paul Lorigan, (unknown), Mary O’Brien, (unknown), S. Zildjian, Albert Qin, James J. O’Leary, Miguel A. Villalona‐Calero	8
17	Time Trends in the Outcome of Elderly Patients with Breast Cancer 2008 ·The Breast Journal ·Sarah Hughes, Yolanda Barbáchano, S. Ashley, Yoon Sim Yap, Sanjay Popat, Mark Allen, (unknown), Stephen Johnston, Ian Smith, Mary O’Brien	8
18	Pemetrexed plus cisplatin (P plus CIS) or carboplatin (P plus CB) in chemonaive malignant pleural mesothelioma (MPM) patients (PTS): Results of the international expanded access program (EAP) 2007 ·Annals of Oncology ·Armando Santoro, Paolo Andrea Zucali, Mary O’Brien, Rolf A. Stahel, Kristiaan Nackaerts, Paul Baas, L. Paz-Ares, Stein Sundstrøm, J. Blatter, C. Manegold	1
19	Vinorelbine alternating oral and intravenous plus carboplatinin advanced non-small-cell lung cancer: results of a multicentre phase II study 2004 ·Annals of Oncology ·Mary O’Brien, Aleksandra Szczęsna, (unknown), Petr Zatloukal, Tim Eisen, Wolfgang Hartmann, Peter Kasan, (unknown), Florence Lefresne	17
20	Compliance Behavior and Long-Term Maintenance Dialysis 1990 ·American Journal of Kidney Diseases ·Mary O’Brien	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact